Vivorte
Louisville, US · Delaware corporation
Vivorté develops and commercializes orthopedic medical devices focused on maintaining or improving bone strength and speeding the healing process for patients, surgeons, hospitals, and payers. It manufactures its products in cleanroom environments and processes biologic tissue under regulated quality standards.
Founders & leadership
TW
Tyree WilburnNamed on SEC filing
WS
William ScheesseleNamed on SEC filing
RV
Ruth VoorCo-Founder, Board of Directors
MV
Michael VoorCo-Founder, Chief Science Officer & Acting President/CEO
RS
Robert SaundersNamed on SEC filing
MW
Mark WagnerNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$4.3M disclosed across 7 rounds · 2015–2022
▶$600.9KraisedJul 2022 · 18 investors · BiotechnologyRule 506(b)
▶$600.9KraisedJul 2022 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark WagnerExecutive Officer
- Peter WeissDirector
- Ruth VoorDirector
- Tyree WilburnDirector
- Michael VoorDirector
- William ScheesseleDirector
- Robert SaundersDirector
- Offering amount
- $2.5M
- Amount sold
- $600.9K
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$321.1KraisedMar 2021 · 15 investors · BiotechnologyRule 506(b)
▶$321.1KraisedMar 2021 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark WagnerExecutive Officer
- Michael VoorDirector
- Robert SaundersDirector
- Peter WeissDirector
- William ScheesseleDirector
- Tyree WilburnDirector
- Ruth VoorDirector
- Offering amount
- $717.1K
- Amount sold
- $321.1K
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$835KraisedSep 2020 · 22 investors · BiotechnologyRule 506(b)
▶$835KraisedSep 2020 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tyree WilburnDirector
- Michael VoorExecutive Officer
- Robert SaundersDirector
- Ruth VoorDirector
- William ScheesseleDirector
- Mark WagnerExecutive Officer
- Offering amount
- $1.7M
- Amount sold
- $835K
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$895KraisedSep 2020 · 14 investors · BiotechnologyRule 506(b)
▶$895KraisedSep 2020 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tyree WilburnDirector
- Robert SaundersDirector
- Michael VoorExecutive Officer
- Ruth VoorDirector
- William ScheesseleDirector
- Mark WagnerExecutive Officer
- Offering amount
- $927.6K
- Amount sold
- $895K
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$350KraisedOct 2019 · 5 investors · BiotechnologyRule 506(b)
▶$350KraisedOct 2019 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tyree WilburnDirector
- Michael VoorExecutive Officer
- Ruth VoorDirector
- William ScheesseleDirector
- Robert SaundersDirector
- Mark WagnerExecutive Officer
- Offering amount
- $350K
- Amount sold
- $350K
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$902.2KraisedNov 2018 · 30 investors · BiotechnologyRule 506(b)
▶$902.2KraisedNov 2018 · 30 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tyree WilburnDirector
- Mark WagnerExecutive Officer
- Robert SaundersDirector
- Michael VoorExecutive Officer
- Ruth VoorDirector
- William ScheesseleDirector
- Offering amount
- $1.5M
- Amount sold
- $902.2K
- Minimum investment
- $10K
- First sale
- Nov 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$410KraisedNov 2018 · 8 investors · BiotechnologyRule 506(b)
▶$410KraisedNov 2018 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tyree WilburnDirector
- William ScheesseleDirector
- Ruth VoorDirector
- Michael VoorExecutive Officer
- Robert SaundersDirector
- Mark WagnerExecutive Officer
- Offering amount
- $1.5M
- Amount sold
- $410K
- Minimum investment
- $25K
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Vivorte do?
- Vivorté develops and commercializes orthopedic medical devices focused on maintaining or improving bone strength and speeding the healing process for patients, surgeons, hospitals, and payers. It manufactures its products in cleanroom environments and processes biologic tissue under regulated quality standards.
- How much funding has Vivorte raised?
- Vivorte has disclosed $4.3M raised across 7 rounds.
- Where is Vivorte headquartered?
- Vivorte is headquartered in Louisville, US.